Litcius/Paper detail

Metastatic Lung Adenocarcinoma Received Combined 177Lu-FAP-2286 Radiation Therapy and Targeted Therapy

Yang Hong-yu, Huipan Liu, Yu Zhang, Yu Zhang, Yue Chen

2024Clinical Nuclear Medicine12 citationsDOI

Abstract

ABSTRACT: A 56-year-old man with metastatic lung adenocarcinoma received combined 177 Lu-FAP-2286 radiation therapy and targeted therapy. After 1 treatment cycle, improvement of symptoms and radiological remission was observed. Moreover, the patient did not report any adverse effects.

Topics & Concepts

MedicineLungRadiation therapyAdverse effectAdenocarcinomaTargeted therapyRadiological weaponOncologyAdenocarcinoma of the lungInternal medicineRadiologyCancerPeptidase Inhibition and AnalysisLung Cancer Research StudiesRadiopharmaceutical Chemistry and Applications
Metastatic Lung Adenocarcinoma Received Combined 177Lu-FAP-2286 Radiation Therapy and Targeted Therapy | Litcius